The Guthy-Jackson Charitable Foundation announces the first volume of its newsletter, "The SPECTRUM." Dedicated to issues relevant to life with Neuromyelitis Optica (NMO) Spectrum Disease, The SPECTRUM offers readers updates about NMO science, alternative persepctives, what the Foundation is doing to help find answers to life with NMO and much more. The SPECTRUM is an online newsletter available in a PDF download.
Please click the link below to read The SPECTRUM.

A team of Mayo Clinic scientists led by Dr. Vanda Lennon recently reported the discovery of a protein targeted by an antibody that distinguishes neuromyelitis optica (NMO, also known as Devic's disease) from more common forms of multiple sclerosis (MS) that are generally less severe. (See publications below.) The antibody is proving to be a valuable blood test for establishing the diagnosis of NMO and related diseases in the early symptom stage. This distinction is important because optimal treatments differ for NMO and MS.